BD Medical to buy anti-needlestick devices developer

12 July 2012 (Last Updated July 12th, 2012 18:30)

Becton, Dickinson and Company (BD) has entered into a definitive agreement to purchase Safety Syringes, a developer of passive needle shields and guards for prefilled syringes.

Becton, Dickinson and Company (BD) has entered into a definitive agreement to purchase Safety Syringes, a developer of passive needle shields and guards for prefilled syringes.

"The acquisition will enable BD to provide Safety Syringe's UltraSafe Passive products to any prefillable syringe customer."

The acquisition will enable BD to provide Safety Syringe's UltraSafe Passive products to any prefillable syringe customer.

UltraSafe Passive products use passive protection to provide a drug delivery system with a safety guard which passively (automatically) locks into place to deliver easy-to-use injury protection and safety.

William Kozy, BD executive vice president, said developments for parenteral drug delivery systems continue to be a part of the company's long-term strategy.

"This acquisition is intended to provide our BD Medical - Pharmaceutical Systems unit with additional safety features for prefillable syringes, helping to protect against accidental needlesticks by providing safer injections for healthcare workers and end users," Kozy added.

Terms of BD's deal with Safety Syringes have not been disclosed.

Claude Dartiguelongue, BD Medical - Pharmaceutical Systems president, said: "We believe BD's prefillable syringe expertise, combined with Safety Syringes' product portfolio and device development expertise, will enable new and innovative safety technology development to prepare the next generation of safety-engineered prefillable syringes."

The acquisition, which is expected to close by the end of BD's fiscal 2012, is subject to the satisfaction of regulatory customary closing conditions.

BD, a manufacturer of instrument systems and reagents, said the transaction is not expected to impact the company's previously communicated 2012 earnings guidance, though it will be minimally dilutive for fiscal 2012.